In patients with advanced NRAS-mutated melanoma previously treated with immune checkpoint inhibitors, the preliminary overall response rate was 38% with bocodepsin and binimetinib compared historically to 16% for binimetinib alone in the NEMO trial [43, 44]. This evidence concerns the gene NRAS and melanoma.